Elan Corporation PLC (ELN.I)

ELN.I on Irish Stock Exchange

11.64EUR
1 Aug 2013
Price Change (% chg)

€0.05 (+0.47%)
Prev Close
€11.64
Open
€11.63
Day's High
€11.68
Day's Low
€11.53
Volume
154,311
Avg. Vol
340,565
52-wk High
€12.57
52-wk Low
€6.83

ELN.I

Chart for ELN.I

About

Elan Corporation, plc (Elan), is a biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. On February 6, 2013, the Company announced that it has entered into an asset purchase agreement with Biogen Idec to transfer to Biogen Idec all Tysabri IP... (more)

Overall

Beta: 0.56
Market Cap (Mil.): €5,907.28
Shares Outstanding (Mil.): 511.59
Dividend: --
Yield (%): --

Financials

  ELN.I Industry Sector
P/E (TTM): -- 47.13 37.76
EPS (TTM): -0.46 -- --
ROI: -27.52 -2.58 18.76
ROE: -52.59 -2.66 19.59
Search Stocks

US STOCKS-Wall St declines as investors focus on Fed policy meeting

* Fed could signal plans about stimulus, jobs data this week as well

29 Jul 2013

US STOCKS-Wall St declines as investors focus on Fed policy meeting

* Fed could signal plans about stimulus, jobs data this week as well

29 Jul 2013

Deals of the day -- mergers and acquisitions

July 29 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

29 Jul 2013

US STOCKS-Wall Street falls as investors eye Fed statement

* Investors turn focus to data, signals from Fed on stimulus

29 Jul 2013

Drugmaker Perrigo to buy Ireland's Elan for $8.6 billion

DUBLIN - U.S. drugmaker Perrigo agreed to buy Elan for $8.6 billion in a deal that will hand it tax savings from being domiciled in Ireland and royalties from a blockbuster multiple sclerosis treatment.

29 Jul 2013

UPDATE 4-U.S. drugmaker Perrigo to buy Ireland's Elan for $8.6 bln

DUBLIN, July 29 - U.S. drugmaker Perrigo agreed to buy Elan for $8.6 billion in a deal that will hand it tax savings from being domiciled in Ireland and royalties from a blockbuster multiple sclerosis treatment.

29 Jul 2013

US STOCKS-Wall Street set to slip at open beginning busy week

* Drug firm Perrigo to buy Elan; Publicis, Omnicom in merger

29 Jul 2013

US STOCKS-Futures dip ahead of key data, Fed meeting this week

* Perrigo to buy Elan; Lord & Taylor's parent to acquire Saks

29 Jul 2013

US STOCKS-Futures dip before key data, Fed meeting this week

* Perrigo to buy Elan, Lord & Taylor's parent to acquire Saks

29 Jul 2013

M&A deals boost European stocks

* Despite recent wave of deals, M&A activity subdued in 2013

29 Jul 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks